| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Acquired resistance in NSCLC: the journey from clinical definition to molecular understanding
|
Wauters, E.
|
|
|
32 |
12 |
p. 1463-1465
|
article
|
| 2 |
Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study
|
Harbeck, N.
|
|
|
32 |
12 |
p. 1571-1581
|
article
|
| 3 |
Adjuvant abemaciclib for high-risk breast cancer: the story continues
|
Spring, L.
|
|
|
32 |
12 |
p. 1457-1459
|
article
|
| 4 |
Aligning tumor mutational burden (TMB) quantification across diagnostic platforms: phase II of the Friends of Cancer Research TMB Harmonization Project
|
Vega, D.M.
|
|
|
32 |
12 |
p. 1626-1636
|
article
|
| 5 |
Analysis of mutation status and homologous recombination deficiency in tumors of patients with germline BRCA1 or BRCA2 mutations and metastatic breast cancer: OlympiAD ☆
|
Hodgson, D.
|
|
|
32 |
12 |
p. 1582-1589
|
article
|
| 6 |
Association of RAD51 with homologous recombination deficiency (HRD) and clinical outcomes in untreated triple-negative breast cancer (TNBC): analysis of the GeparSixto randomized clinical trial
|
Llop-Guevara, A.
|
|
|
32 |
12 |
p. 1590-1596
|
article
|
| 7 |
Bone sarcomas: ESMO–EURACAN–GENTURIS–ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up ☆
|
Strauss, S.J.
|
|
|
32 |
12 |
p. 1520-1536
|
article
|
| 8 |
Clinical definition of acquired resistance to immunotherapy in patients with metastatic non-small-cell lung cancer
|
Schoenfeld, A.J.
|
|
|
32 |
12 |
p. 1597-1607
|
article
|
| 9 |
Corrigendum to ‘First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis’
|
Emens, L.A.
|
|
|
32 |
12 |
p. 1650
|
article
|
| 10 |
Detection of additional occult malignancy through profiling of ctDNA in late-stage cancer patients
|
Aldea, M.
|
|
|
32 |
12 |
p. 1642-1645
|
article
|
| 11 |
Early and locally advanced non-small-cell lung cancer: an update of the ESMO Clinical Practice Guidelines focusing on diagnosis, staging, systemic and local therapy
|
Remon, J.
|
|
|
32 |
12 |
p. 1637-1642
|
article
|
| 12 |
Editorial Board
|
|
|
|
32 |
12 |
p. iii
|
article
|
| 13 |
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer ☆
|
Gennari, A.
|
|
|
32 |
12 |
p. 1475-1495
|
article
|
| 14 |
ESMO Clinical Practice Guideline update on the use of immunotherapy in early stage and advanced renal cell carcinoma
|
Powles, T.
|
|
|
32 |
12 |
p. 1511-1519
|
article
|
| 15 |
ESMO guidelines on renal cell carcinoma: the paradox of the fine line that separates scientific robustness from cost-efficiency analysis
|
Grande, E.
|
|
|
32 |
12 |
p. 1466-1467
|
article
|
| 16 |
Essential digital health
|
Scotte, F.
|
|
|
32 |
12 |
p. 1468-1469
|
article
|
| 17 |
Lesion-level heterogeneity of radiologic progression in patients treated with pembrolizumab
|
Topp, B.G.
|
|
|
32 |
12 |
p. 1618-1625
|
article
|
| 18 |
Liquid biopsy in neuro-oncology: are we finally there?
|
Fontanilles, M.
|
|
|
32 |
12 |
p. 1472-1474
|
article
|
| 19 |
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis treatment and follow-up of patients with localised colon cancer
|
Yoshino, T.
|
|
|
32 |
12 |
p. 1496-1510
|
article
|
| 20 |
PARP inhibitor sensitivity in BRCA-related metastatic breast cancer: an OlympiAD later
|
Fuentes-Antrás, J.
|
|
|
32 |
12 |
p. 1460-1462
|
article
|
| 21 |
Table of Contents
|
|
|
|
32 |
12 |
p. i-ii
|
article
|
| 22 |
The efficacy, challenges, and facilitators of telemedicine in post-treatment cancer survivorship care: an overview of systematic reviews
|
Chan, R.J.
|
|
|
32 |
12 |
p. 1552-1570
|
article
|
| 23 |
The ESMO-EURACAN-GENTURIS-ERNPaedCan Clinical Practice Guidelines for bone sarcomas – the challenges of the fight against rare cancers
|
Andreou, D.
|
|
|
32 |
12 |
p. 1470-1471
|
article
|
| 24 |
Therapeutic cancer vaccines revamping: technology advancements and pitfalls
|
Antonarelli, G.
|
|
|
32 |
12 |
p. 1537-1551
|
article
|
| 25 |
The TeloDIAG: how telomeric parameters can help in glioma rapid diagnosis and liquid biopsy approaches
|
Billard, P.
|
|
|
32 |
12 |
p. 1608-1617
|
article
|
| 26 |
VP8-2021: Adjuvant abemaciclib combined with endocrine therapy (ET): Updated results from monarchE
|
O'Shaughnessy, J.
|
|
|
32 |
12 |
p. 1646-1649
|
article
|
Journal description